在过去的十年中，T细胞定向疗法，包括嵌合抗原受体T细胞（CAR-T）和双特异性T细胞接合器（BTE）疗法，重塑了越来越多的血液恶性肿瘤的治疗方法，而肿瘤浸润淋巴细胞（ TIL）是最近批准的一种细胞疗法，针对实体瘤恶性肿瘤。新数据表明，这些疗法可能与严重心脏毒性的高发生率有关，包括心房颤动、心力衰竭、室性心律失常和其他心血管毒性。这些事件的发生是这些治疗后长期生存的主要限制。本综述探讨了当前的证据状况，包括报告的发病率、危险因素、机制和使用这些新疗法治疗后心血管毒性的管理策略。我们特别关注 CAR-T、BTE 及其与心律失常、心力衰竭、心肌炎、出血和其他主要心血管事件的关系。除了细胞因子释放综合征与心脏毒性之间的关系之外，我们还描述了其他潜在机制，并强调了尚未解答的关键问题和未来的研究方向。版权所有 © 2024 美国血液学会。

Over the past decade, T-cell directed therapies, including chimeric antigen receptor T-cell (CAR-T) and bispecific T-cell engager (BTE) therapy have reshaped the treatment of an expanding number of hematologic malignancies, while tumor infiltrating lymphocytes (TILs), a recently approved cellular therapy, targets solid tumor malignancies. Emerging data suggests that these therapies may be associated with a high incidence of serious cardiotoxicities, including atrial fibrillation, heart failure, ventricular arrhythmias, and other cardiovascular toxicities. The development of these events is a major limitation to long-term survival following these treatments. This review examines the current state of evidence, including reported incidence rates, risk factors, mechanisms, and management strategies of cardiovascular toxicities following treatment with these novel therapies. We specifically focus on CAR-T, BTE, and their relation to arrhythmias, heart failure, myocarditis, bleeding, and other major cardiovascular events. Beyond the relationship between cytokine release syndrome and cardiotoxicity, we describe other potential mechanisms and highlight key unanswered questions and future directions of research.Copyright © 2024 American Society of Hematology.